Breast Cancer - Survival

Taxol Improves Survival in Advanced Breast Cancer
Women with metastatic breast cancer have better survival rates and fewer side effects when treated with Taxol (paclitaxel), instead of a standard chemotherapy combination of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP), according to a study conducted at the Sydney Cancer Center in Sydney, Australia. In women receiving each regimen as first-line treatment for advanced cancer, two-year survival was 20 percent in the CMFP group versus 39 percent in the Taxol group. The Taxol group also had fewer side effects, primarily hair loss, nerve symptoms, and joint and muscle pains. The CMFP group suffered nausea and vomiting, loss of white blood cells and platelets, and other symptoms.

Bishop JF, Dewar J, Toner GC, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol. 1999;17:2355.

The Web site does not provide medical or legal advice.
This site is for information purposes only.
Full Disclaimer | Privacy Policy